Concepedia

Colin Bath

CB

Statistics

Publications

3

Citations

61

H-Index

3

Active since

1997

Affiliations

AstraZeneca (United Kingdom)(Current)

Colin Bath is an author at AstraZeneca (United Kingdom) specializing in drug discovery, medicine, and pharmacology.

Top concepts

MedicinePharmacologyDrug DiscoveryMedicinal ChemistryUltrasoundBioanalysisBiomedicineEngineeringBiochemistryMicrofluidics

Publications per year

1997–2012

3

Publications

3

New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure−Activity Relationships of 5-(Dimethylamino)-<i>N</i>-pyridyl-, -<i>N</i>-pyrimidinyl-, -<i>N</i>-pyridazinyl-, and -<i>N</i>-pyrazinyl-1-naphthalenesulfonamides

Robert H. Bradbury, Colin Bath, Roger J. Butlin et al. · Journal of Medicinal Chemistry · 1997 · 30 citations · Full text

Combinatorial Chemistry, Automated Synthesis, Biological Properties +17

Implementation and Development of an Automated, Ultra-High-Capacity, Acoustic, Flexible Dispensing Platform for Assay-Ready Plate Delivery

Dylan Griffith, Roger Northwood, Paul Owen et al. · SLAS TECHNOLOGY · 2012 · 21 citations · Full text

Biomedical Acoustics, Pharmaceutical Research, Engineering +24

N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide; one of a class of novel benzenesulphonamides which are orally-active, ETA-selective endothelin antagonists

Andrew Mortlock, Colin Bath, Roger J. Butlin et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 10 citations

Eta-selective Endothelin Antagonists, Medicinal Chemistry, Medicine +7

1–3 of 3